Tag: Hiv prevention

According to the DISCOVER trial, switching from Truvada to Descovy for pre-exposure prophylaxis (PrEP) led to measurable improvements in markers of kidney function and bone mineral density. This evidence highlights the distinct pharmacological profiles of these two antiretrovirals, which is a primary reason why some individuals and their healthcare providers consider a switch from Truvada to Descovy.

Following two separate FDA approvals, **is lenacapavir available in the US** for both the treatment of multi-drug resistant HIV and for HIV prevention (PrEP). The latter, approved in June 2025, represents a significant step forward with its injectable administration, offering a novel, long-acting option for eligible individuals.

As of late 2025, there is no therapeutically equivalent generic cabotegravir available for commercial use in the United States, although efforts via the Medicines Patent Pool aim to provide access in low- and middle-income countries. This article addresses the question, is there a generic for cabotegravir, and details the current situation regarding brand-name formulations and global access initiatives.

PrEP is over 99% effective at preventing HIV from sex when taken consistently as prescribed. Knowing what not to do while on PrEP, such as missing doses or ignoring drug interactions, is crucial for maintaining this high level of protection and ensuring overall health.

According to the IPERGAY trial, the 2-1-1 rule for tenofovir, an intermittent PrEP regimen, showed 86% effectiveness in preventing HIV transmission among men who have sex with men (MSM). This alternative to daily dosing offers a different approach to pre-exposure prophylaxis for individuals who can anticipate their sexual activity.

Following its FDA approval in June 2025, Yeztugo (lenacapavir) became the first and only twice-yearly injectable option for HIV pre-exposure prophylaxis (PrEP) in the United States. For those asking, 'Is Yeztugo available?', the answer is yes in the United States, representing a significant advancement in HIV prevention by simplifying the dosing schedule and addressing adherence barriers.

Named the "Breakthrough of the Year" by *Science* magazine in 2024, lenacapavir is a first-in-class, long-acting medication used for both the treatment of multi-drug resistant HIV and for pre-exposure prophylaxis (PrEP). It is a capsid inhibitor that acts on the virus in multiple stages of its lifecycle, a novel approach compared to older antiretroviral therapies.

In recent clinical trials, lenacapavir demonstrated a 96% lower incidence of HIV infection compared to background incidence for prevention. This incredible efficacy stems from the fact that lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor, offering a groundbreaking new approach to managing and preventing HIV.

In 2022, over 2.5 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States. While no single medication prevents all sexually transmitted diseases, the question 'What pill blocks STDs?' leads to two key biomedical interventions: Doxycycline Post-Exposure Prophylaxis (DoxyPEP) and Pre-Exposure Prophylaxis (PrEP).